CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma

Overview of attention for article published in Frontiers in oncology, February 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 11 X posts from 11 X users, with an upper bound of 17,506 followers.

RT @CARTTherapy: CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma #CART #bmtsm #CARTcell #immunotherapy…

RT @CARTTherapy: CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma #CART #bmtsm #CARTcell #immunotherapy…

RT @CARTTherapy: CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma #CART #bmtsm #CARTcell #immunotherapy…

RT @CARTTherapy: CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma #CART #bmtsm #CARTcell #immunotherapy…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.